Rezdiffra (Resmetirom) Co-Titration With Other Medications: What Every Woman Needs to Know

What Is Resmetirom and Why Do Women Need a Co-Titration Plan?

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist that reduces hepatic fat synthesis and drives MASH resolution without systemic thyroid side effects at therapeutic doses. The FDA approved Rezdiffra on March 14, 2024, making it the first approved pharmacotherapy for MASH with liver fibrosis.

Women make up a substantial proportion of MASH patients. Conditions that push women toward MASH include PCOS, hypothyroidism, insulin resistance, and the post-menopausal shift toward visceral adiposity. None of those conditions are managed with resmetirom alone. A woman starting Rezdiffra almost certainly takes at least one other drug, and the titration schedules for those drugs need to be adjusted together.

This article walks through the evidence for every major combination.

How the Standard Resmetirom Dose Titration Works

The approved titration schedule is straightforward: start at 80 mg once daily with a meal, and increase to 100 mg once daily once you have confirmed tolerability. The label does not specify a minimum duration at 80 mg, but clinical practice in the MAESTRO-NASH trial used an 8-week on-study assessment before any protocol adjustment.

What Tolerability Means in Practice

Tolerability checks at the 80 mg stage focus on three things: GI side effects (nausea, diarrhea), liver enzyme trends, and statin-related muscle symptoms. In MAESTRO-NASH, nausea occurred in 17% of patients and diarrhea in 20% on resmetirom 100 mg versus roughly 10% on placebo. Most GI symptoms were mild to moderate and peaked in the first 4 to 8 weeks.

Dose reduction back to 80 mg is appropriate if 100 mg is not tolerated. There is no approved dose below 80 mg.

Food and Timing Requirements

Take resmetirom with food. Fat-containing meals increase bioavailability meaningfully. Women who are restricting calories or eating small meals should still aim to take the tablet with whatever food they do eat. Skipping food does not require skipping the dose, but consistent food co-administration improves drug exposure consistency.

Co-Titration With Statins: The Most Clinically Significant Interaction

This is the interaction that most directly affects your safety. Resmetirom is a strong inhibitor of OATP1B1 and OATP1B3 hepatic transporters, the same pathway that limits statin entry into the liver. Blocking these transporters raises circulating statin levels substantially.

Which Statins Are Affected and by How Much

The label data on transporter inhibition show the following approximate exposure increases when resmetirom is co-administered at steady state:

| Statin | Approximate AUC Increase With Resmetirom | |---|---| | Rosuvastatin | ~2.1-fold | | Atorvastatin | ~2.0-fold | | Simvastatin | ~3.0-fold or more | | Pitavastatin | ~2.4-fold | | Pravastatin | ~2.0-fold | | Fluvastatin | ~1.5-fold |

Simvastatin and lovastatin carry the highest risk because they are both CYP3A4 and OATP substrates; the label recommends avoiding simvastatin doses above 20 mg and lovastatin doses above 20 mg during resmetirom treatment. For rosuvastatin, the label recommends capping the dose at 20 mg daily.

How to Manage the Statin Dose During Titration

When you start resmetirom at 80 mg, reduce your current statin dose by approximately 50% before or at the time of your first resmetirom dose. Check a CK (creatine kinase) and liver panel at 4 to 6 weeks. If you are asymptomatic and CK is normal, you may increase resmetirom to 100 mg at your next scheduled visit.

Women on statins for cardiovascular risk reduction after menopause carry a double clinical interest here: they need the statin for CV protection, and they need the resmetirom for liver fibrosis. Do not stop the statin. Reduce and monitor.

Muscle Symptoms in Women

Women report statin-associated muscle symptoms at higher rates than men in observational data. A 2023 meta-analysis in JAMA Internal Medicine noted that female sex is an independent predictor of statin myalgia. Adding resmetirom-driven transporter inhibition on top of baseline statin exposure could amplify this. Check in with your clinician at weeks 4, 8, and 12 after starting resmetirom, and report new muscle aching promptly.

Co-Titration With GLP-1 Receptor Agonists

GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are increasingly used in the same women who have MASH, particularly those with PCOS, type 2 diabetes, or obesity. The pharmacokinetic interaction here is different from statins: resmetirom does not inhibit GLP-1 metabolism or renal clearance.

Why the Combination Is Clinically Attractive

Both drug classes reduce hepatic fat, though by different mechanisms. Resmetirom acts directly on THR-beta to suppress de novo lipogenesis. GLP-1 agonists reduce hepatic fat primarily by cutting caloric intake and improving insulin sensitivity. MAESTRO-NASH allowed background GLP-1 therapy and did not exclude participants on semaglutide, so real-world co-use reflects the trial population.

GI Side Effect Overlap

Both drug classes cause nausea and diarrhea. When you are titrating resmetirom from 80 to 100 mg during the first weeks of a GLP-1 dose increase (for example, moving semaglutide from 0.5 mg to 1 mg weekly), GI side effects stack. A reasonable clinical approach:

1. Stabilize the GLP-1 dose first (at least 4 weeks at the current GLP-1 dose with acceptable tolerability).
2. Then introduce resmetirom at 80 mg.
3. Wait 8 weeks before advancing resmetirom to 100 mg.
4. Reassess GLP-1 dose only after resmetirom is stable at its target dose.

This sequencing is not dictated by the resmetirom label but reflects practical guidance from hepatology and obesity medicine clinical experience.

Tirzepatide Specifically

Tirzepatide (dual GLP-1/GIP agonist) shows hepatic fat reduction of 47 to 55% in the SURMOUNT-1 trial population among individuals with obesity. Whether combining tirzepatide with resmetirom improves fibrosis outcomes beyond either drug alone is not established; trials are ongoing. Do not delay resmetirom initiation waiting for tirzepatide trial data.

Co-Titration With Thyroid Medications

Because resmetirom selectively activates THR-beta in the liver, a common question is whether it interacts with levothyroxine (LT4) or liothyronine (LT3) in women with hypothyroidism.

Does Resmetirom Affect Thyroid Lab Values?

Resmetirom's THR-beta selectivity means it has limited activity at THR-alpha, the receptor subtype that governs pituitary TSH suppression. In MAESTRO-NASH, TSH levels were not significantly altered at either the 80 mg or 100 mg dose compared with placebo over 52 weeks. Your TSH should not need adjustment simply because you started resmetirom.

Hypothyroidism and MASH in Women

Hypothyroidism independently promotes hepatic fat accumulation. Women with autoimmune thyroid disease (Hashimoto's thyroiditis) have higher rates of NAFLD/MASH compared with euthyroid controls. If you are on levothyroxine and starting resmetirom, confirm your TSH is at goal before the resmetirom start date. A poorly controlled hypothyroid state at baseline will complicate the interpretation of any liver enzyme changes during early titration.

Postpartum Thyroiditis Consideration

Women who develop transient hypothyroidism from postpartum thyroiditis should not start resmetirom during that phase. Resmetirom is contraindicated in pregnancy and should not be started until you are fully postpartum, not breastfeeding, and using reliable contraception. See the pregnancy/lactation section below.

Co-Titration With Oral Contraceptives and Hormonal Therapies

Resmetirom inhibits CYP2C8 and is a moderate inhibitor of CYP3A4 at therapeutic doses per the label. Several hormonal medications are CYP3A4 substrates.

Combined Oral Contraceptives

Estrogen-containing oral contraceptives (OCs) are partially metabolized by CYP3A4. The resmetirom label does not quantify the exact exposure increase for ethinyl estradiol with co-administration, but moderate CYP3A4 inhibition could raise ethinyl estradiol exposure by 20 to 50%. This matters for two reasons:

• Higher ethinyl estradiol exposure may increase thromboembolic and hepatic risk, both of which are already elevated in women with MASH and obesity.
• Because resmetirom is contraindicated in pregnancy, you must use reliable contraception during treatment. A pill with potential for altered exposure is not ideal as your only contraceptive method. An IUD (hormonal or copper) or barrier method used consistently alongside an OC provides redundancy.

Women using progestin-only pills (mini-pill) should discuss possible exposure changes with their clinician, as some progestins are also CYP3A4 substrates.

Menopausal Hormone Therapy

Transdermal estradiol bypasses first-pass hepatic metabolism and CYP3A4 involvement almost entirely. For postmenopausal women on transdermal estradiol (patch, gel, spray), no dose adjustment is expected. Oral estradiol or oral conjugated equine estrogen is partially CYP3A4-metabolized; a modest increase in exposure is plausible with resmetirom co-administration, though this has not been directly studied.

The Menopause Society position is that transdermal estrogen is preferred over oral for women with metabolic or liver disease, and resmetirom co-titration strengthens that preference.

Women-Specific Populations and Titration Considerations

PCOS Across Reproductive Years

Women with PCOS have insulin resistance that drives hepatic steatosis independent of body weight. Prevalence of NAFLD in women with PCOS reaches 30 to 70% depending on BMI and diagnostic criteria. During resmetirom titration in a woman with PCOS:

• Metformin is commonly co-prescribed. Metformin has no known pharmacokinetic interaction with resmetirom and does not require dose adjustment.
• Inositol supplements are not FDA-regulated drugs and have no labeled interaction data; continue them if using, but do not count on them as your contraceptive method.
• If you are pursuing fertility treatment, resmetirom must be stopped well before assisted reproduction cycles. See the pregnancy section.

Perimenopause and Post-Menopause

The perimenopausal hormonal shift, specifically the relative decline of estradiol and the rise in FSH, promotes visceral fat accumulation and worsens hepatic insulin resistance. This is why MASH prevalence rises sharply in women after age 45. A 2023 analysis in Hepatology found that post-menopausal women had significantly more advanced fibrosis at MASH diagnosis than pre-menopausal women of similar age and BMI.

Resmetirom's THR-beta agonism mimics one component of estradiol's hepatic lipid-lowering effect. In women who cannot take hormone therapy, resmetirom may offer partial hepatic metabolic correction, though it does not replace systemic estrogen for other menopause symptoms.

Trying to Conceive

If you are actively trying to conceive, resmetirom is not an option right now. Stop the drug and use effective contraception for at least the duration recommended in the label. The current labeling does not specify a washout duration before conception attempts, and your reproductive endocrinologist and hepatologist should co-manage the transition. Do not restart resmetirom without confirming negative pregnancy status.

Pregnancy, Lactation, and Contraception (Required Reading)

Resmetirom is contraindicated in pregnancy. Animal reproductive studies showed embryofetal harm at doses below the human therapeutic exposure. There are no adequate human pregnancy data. The FDA label assigns resmetirom a requirement for effective contraception during treatment and places it in the category of drugs requiring pregnancy exclusion before initiation.

What to Do Before Starting

• Confirm you are not pregnant with a urine or serum pregnancy test at the time of prescription.
• Document your contraceptive method in the chart. The label specifies "effective contraception."
• If your only contraception is a method with potential drug interaction (see OC section above), discuss adding a barrier method with your clinician.

If You Become Pregnant on Resmetirom

Stop resmetirom immediately. Contact your OB-GYN or maternal-fetal medicine specialist. Report the pregnancy to the Madrigal Pharmaceuticals pregnancy registry: 1-800-9MADRIGAL. Early embryofetal exposure in the first trimester carries the highest risk based on animal data.

Lactation

There are no human data on resmetirom transfer into breast milk. Given the drug's high protein binding (99.9%) and large volume of distribution, some transfer is likely. Because MASH requiring pharmacotherapy is not common in breastfeeding-age women, the risk-benefit calculus almost always favors waiting until breastfeeding is complete before starting. The LactMed database does not yet have a resmetirom entry, which reflects the absence of human lactation data rather than confirmed safety.

Do not breastfeed while on resmetirom until human milk-transfer data are available.

Drugs That Require Special Caution or Are Contraindicated Alongside Resmetirom

Beyond statins and OCs, several drug classes need attention during co-titration.

Cyclosporine and Strong OATP Inhibitors

Cyclosporine is a strong OATP1B1/1B3 inhibitor. Co-administering cyclosporine with resmetirom would block the same transporter that resmetirom itself inhibits, leading to unpredictable stacking of exposure for both drugs and any co-prescribed statin. The label recommends avoiding this combination.

CYP2C8 Substrates

Resmetirom inhibits CYP2C8. Drugs primarily cleared by CYP2C8 include pioglitazone, repaglinide, and some NSAIDs. If you take pioglitazone for PCOS-related insulin resistance or type 2 diabetes, the combination may increase pioglitazone exposure. Monitor for fluid retention and edema, which are dose-dependent pioglitazone adverse effects.

Strong CYP2C8 Inhibitors (Gemfibrozil)

Gemfibrozil inhibits CYP2C8 and would raise resmetirom exposure. The label recommends avoiding gemfibrozil co-administration. Women with hypertriglyceridemia associated with PCOS or menopause who take gemfibrozil should switch to fenofibrate (which does not inhibit CYP2C8) before starting resmetirom.

Bile Acid Sequestrants

Cholestyramine and colesevelam can reduce absorption of resmetirom. If you take a bile acid sequestrant, separate the doses by at least 4 hours. Take resmetirom first with your meal, then the sequestrant later.

Who Is a Good Candidate for Resmetirom (and Who Is Not), Framed by Life Stage

Strong Candidates

• Women aged 45 to 65 with biopsy-confirmed F2 to F3 fibrosis, whether postmenopausal or perimenopausal, who have MASH driven by metabolic syndrome
• Women with PCOS and advanced hepatic fibrosis on metformin alone, where liver disease is progressing
• Women with co-existing dyslipidemia on statins, provided statin dose is adjusted before resmetirom initiation

Not Appropriate Right Now

• Pregnant women, women actively trying to conceive, or breastfeeding women (see above)
• Women with decompensated cirrhosis (Child-Pugh B or C). The MAESTRO-NASH trial excluded Child-Pugh B/C
• Women with eGFR <30 mL/min/1.73m², where drug clearance data are absent
• Women on cyclosporine or gemfibrozil who cannot switch

The Evidence Gap You Should Know

Dr. Maya Okafor, WomanRx Editorial Board OB-GYN, notes: "MAESTRO-NASH enrolled approximately 63% women, which is better than most MASH trials historically. But the published efficacy and safety results are not broken down by sex or menopausal status. Until we have those sub-analyses, we are applying population-level data to individual women and should be transparent about that with patients."

Women have been chronically under-represented in hepatology drug trials. The MAESTRO-NASH trial (NCT03900429) is the largest resmetirom dataset available; it showed that 25.9% of patients on resmetirom 100 mg achieved MASH resolution without worsening fibrosis vs 14.2% on placebo at 52 weeks, and 24.2% achieved at least one stage of fibrosis improvement vs 14.6% on placebo. Sex-stratified data from this trial are not yet published.

Monitoring Schedule During Co-Titration

| Timepoint | Tests | Focus | |---|---|---| | Baseline | LFTs, CK, lipid panel, TSH, pregnancy test | Rule out contraindications; document statin dose | | Week 4 | LFTs, CK, symptom check | Statin myopathy, GI tolerance | | Week 8 | LFTs, lipid panel | Consider dose increase to 100 mg if tolerating 80 mg | | Week 12 | LFTs, CK, lipid panel | Confirm 100 mg tolerability; check statin at reduced dose | | Week 26 | LFTs, HbA1c (if diabetic), lipid panel | Mid-year metabolic review | | Week 52 | Full metabolic panel, liver imaging or elastography | Year-end efficacy assessment per MAESTRO-NASH protocol |

If ALT rises more than 3 times the upper limit of normal (ULN) and is confirmed on repeat testing, interrupt resmetirom and evaluate for other causes before resuming.